Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Bitcoin Reclaims $60K Amid Wider Crypto Market Recovery

Bitcoin Reclaims $60K Amid Wider Crypto Market Recovery

DailyCoinDailyCoin2024/08/10 00:27
By:DailyCoin
  • Bitcoin has made its way past the $60,000 level.
  • The development comes after the crypto asset’s steep plunge last weekend.
  • Smaller cryptos rallied in tandem with BTC.

On Friday, Bitcoin (BTC) added to its Thursday gains, the largest single-day jump in 16 months, to cross the $60,000 mark for the first time since last weekend’s bloodbath.

The development marks a notable shift for the original cryptocurrency, which had tumbled to its lowest level since February only a few days ago amid a wider global market turmoil. BTC bottomed at $49,781 on August 5 as the wider crypto market cap plunged from $2.16 trillion to $1.76 trillion within a few hours.

Bitcoin Regains Momentum Alongside Smaller Cryptos

Following Thursday’s steady rally, Bitcoin gained over 7% to flirt briefly with $62,000 early Friday before paring some gains to exchange hands at $61,056 at the time of writing.

Sponsored

CoinMarketCap data shows smaller cryptos rallied with the world’s largest digital asset to claim new weekly highs. Ether gained the most with its 24-hour 10.69% surge, as BNB, Solana, and Dogecoin rallied 4.76%, 2.05%, and 5.05%, respectively.

Various developments in the last day could have contributed to this market recovery, including the massive inflow of $194.6 million into spot Bitcoin ETFs on August 8. The influx of new investors and capital likely boosted Bitcoin’s price, pulling other cryptos up.

At the same time, Russian President Vladimir Putin signed a bill that legalizes crypto mining in the country. The move validated crypto’s legitimacy among governments and likely restored investor confidence in risky assets.

Sponsored

Stay updated on Metaplanet’s new Bitcoin acquisition plan:
Metaplanet Eyes $69.6M Bitcoin Acquisition After New Fundraising

Is the IMF about to endorse Bitcoin? Find out in this article:
IMF Warms to Bitcoin: What’s Behind the Shift?

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The "Outlier" Investment Art in the New Era of Berky

他山之石观投资2026/09/14 09:22
The "Outlier" Investment Art in the New Era of Berky

Chevron (CVX.US) explores alternative hedging for Middle East supply disruptions: targets Argentina and the Mediterranean to drive global LNG growth, seeks deal with India

Chevron is focusing on Argentina and the Mediterranean region, seeking global growth in liquefied natural gas, and plans to reach an agreement with India.

智通财经2026/09/14 09:12
Chevron (CVX.US) explores alternative hedging for Middle East supply disruptions: targets Argentina and the Mediterranean to drive global LNG growth, seeks deal with India

Energy and food price pressures intensify, potentially triggering an inflation rebound! The Bank of England may struggle to remain "calm" as market rate hike bets surge

The upward pressure on energy prices caused by the unresolved Middle East war is mounting. New risks are also approaching, which may keep inflation above the Bank of England’s 2% target for most of next year.

智通财经2026/09/14 08:57
Energy and food price pressures intensify, potentially triggering an inflation rebound! The Bank of England may struggle to remain "calm" as market rate hike bets surge

AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales

Bloomberg Intelligence analyst John Murphy stated that the setback in AstraZeneca's breast cancer drug trial could reduce sales in 2035 by $2.6 billion to $3.8 billion.

智通财经2026/09/14 08:41
AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales